CN109206423B - Thioamide substituted dihydropyrrolopyridine compounds as ROR gamma inhibitors - Google Patents
Thioamide substituted dihydropyrrolopyridine compounds as ROR gamma inhibitors Download PDFInfo
- Publication number
- CN109206423B CN109206423B CN201810731382.3A CN201810731382A CN109206423B CN 109206423 B CN109206423 B CN 109206423B CN 201810731382 A CN201810731382 A CN 201810731382A CN 109206423 B CN109206423 B CN 109206423B
- Authority
- CN
- China
- Prior art keywords
- compounds
- compound
- ror
- reaction
- present application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title description 5
- 125000001391 thioamide group Chemical group 0.000 title description 3
- JKWQHCSGMTWRIQ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NCCC2=N1 JKWQHCSGMTWRIQ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 230000001404 mediated effect Effects 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- 238000006243 chemical reaction Methods 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 238000012360 testing method Methods 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- -1 dihydropyrrolopyridine compound Chemical class 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 210000003722 extracellular fluid Anatomy 0.000 description 8
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 8
- 239000008389 polyethoxylated castor oil Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 210000002977 intracellular fluid Anatomy 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013100 final test Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- GGERGLKEDUUSAP-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbaldehyde Chemical group C1=C(C=O)C=C2OC(F)(F)OC2=C1 GGERGLKEDUUSAP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DWLQYXFFOVOCSX-UHFFFAOYSA-N 3,5-difluoro-4-(trifluoromethoxy)benzaldehyde Chemical compound FC=1C=C(C=O)C=C(C=1OC(F)(F)F)F DWLQYXFFOVOCSX-UHFFFAOYSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- RQLRUBHAAVGRPW-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethoxy)benzaldehyde Chemical group FC1=CC(C=O)=CC=C1OC(F)(F)F RQLRUBHAAVGRPW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 102000042839 ROR family Human genes 0.000 description 1
- 108091082331 ROR family Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000014725 late viral mRNA transcription Effects 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The compound of formula (I) or pharmaceutically acceptable salt thereof provided by the invention has good ROR gamma inhibitory activity and is expected to be used for treating diseases mediated by ROR gamma receptors in mammals.
Description
Cross Reference to Related Applications
This application claims priority and benefit from the chinese patent application No. 201710552918.0 filed on 2017, month 07 to the chinese intellectual property office, the contents of which are incorporated herein by reference in their entirety.
Technical Field
The invention relates to a thioamide substituted dihydropyrrolopyridine compound serving as a ROR gamma inhibitor, belonging to the field of medical chemistry.
Background
Retinoic acid-related orphan nuclear receptors (RORs) are members of the nuclear receptor family, which are capable of modulating a variety of physiological and biochemical processes. The ROR family includes three types ROR α, ROR β, and ROR γ. Three different RORs can be expressed in different tissues and regulate different physiological processes. ROR α is distributed mainly in liver, skeletal muscle, skin, lung, adipose tissue, kidney, thymus and brain; ROR β acts primarily on the central nervous system; ROR γ can be expressed in many tissues, including liver, animal fat and skeletal muscle.
There are two subtypes of ROR γ: ROR γ 1 and ROR γ t (ROR γ 2). ROR γ 1 is found in many tissues, such as: thymus, muscle, kidney and liver, while ROR γ t is expressed only in immune cells. ROR γ T is thought to regulate T cell helper T17 (Th17) differentiation. Th17 is a type of T helper cell that produces interleukin 17(IL-17) and other cytokines. Th17 cells are implicated in the pathology of numerous autoimmune and inflammatory diseases including, but not limited to, psoriasis, multiple sclerosis, rheumatoid arthritis, crohn's disease, asthma, chronic obstructive pulmonary disease, Behcet's disease, and irritable bowel syndrome.
Patent applications of Vitae Pharmaceuticals Inc in the prior art, such as WO2014179564, WO2015116904, WO2016061160, etc.; and patent applications of the Puerarin Schke company, such as WO2013045431, WO2013160418, WO2013160419 and the like, all disclose a series of compounds which can be used as ROR gamma inhibitors. In view of the great potential value of ROR gamma inhibitors, it is necessary to further search for compounds having ROR gamma inhibitory function.
Disclosure of Invention
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof,
wherein,
m is 0 or 1;
n is 0, 1 or 2;
R1、R2、R4independently selected from hydrogen or C1-6An alkyl group;
R3、R5independently selected from hydrogen or C1-6An alkyl group; said C is1-6Alkyl is optionally substituted by one or more hydroxy, amino, nitro, cyano, halogen, C1-4Alkoxy radical, C1-4Alkylamino or di (C)1-4Alkyl) amino substitution;
Cy1selected from the group consisting of optionally substituted by one or more R6Substituted 3-6 membered cycloalkyl, 5-8 membered cycloalkenyl, 3-10 membered heterocyclo, 6-10 membered aryl or 5-10 membered heteroaryl;
R6selected from hydroxy, amino, nitro, cyano, halogen, C1-4Alkyl radical, C1-4Haloalkyl, C1-4Alkoxy radical, C1-4A haloalkoxy group;
Cy2selected from 6-10 membered aryl or 5-10 membered heteroaryl; said 6-10 membered aryl or 5-10 membered heteroaryl is optionally substituted with one or more hydroxy, amino, nitro, cyano orSubstitution;
R7presence or absence; when R is7When the water-soluble polymer is existed in the water,is selected from
R8Is selected from C1-6Alkyl or C1-6An alkoxy group.
In some embodiments, m ═ 0; n is 0 or 1.
In some exemplary embodiments, m is 0 and n is 0.
In some embodiments, R1、R2、R4Independently selected from hydrogen or C1-4An alkyl group.
In some typical embodiments, R1、R2、R4Independently selected from hydrogen, methyl, ethyl, n-propyl or isopropyl.
In some more typical embodiments, R1、R2、R4Independently selected from hydrogen or isopropyl.
In some of the most typical embodiments, R1、R2、R4At least one of which is isopropyl.
In some of the most typical embodiments, R1And R4Is hydrogen, and R2Is isopropyl.
In some embodiments, R3、R5Independently selected from hydrogen or C1-3Alkyl radical, said C1-3Alkyl is optionally substituted with one or more hydroxy, amino, nitro, cyano, fluoro, chloro, bromo, iodo, methoxy, ethoxy, methylamino or ethylamino groups.
In some typical embodiments, R3、R5Independently selected from hydrogen, methyl or ethyl, said methyl or ethyl being optionally substituted with one hydroxy, methoxy or ethoxy group.
In some more typical embodiments, R3Selected from hydrogen or methyl, said methyl being optionally substituted by hydroxyl; and R is5Selected from hydrogen or methyl, said methyl being optionally substituted by hydroxyl or methoxy.
In some of the most typical embodiments, R3Selected from hydrogen, methyl or hydroxymethyl; and R is5Selected from hydrogen, methyl, hydroxymethyl or-CH2OCH3。
In some embodiments, Cy is1Selected from the group consisting of6Substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxiranyl, tetrahydrofuryl, dihydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1, 3-cyclohexadienyl, benzo [ d][1,3]Dioxolyl, phenyl, thienyl, furyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, pyridyl, pyrazinyl or pyrimidinyl.
In some typical embodiments, Cy1Selected from the group consisting of6Substituted cyclohexyl, cyclohexenyl, benzo [ d ]][1,3]Dioxolyl, phenyl, pyridyl or pyrimidinyl.
In some embodiments, R6Selected from the group consisting of fluorine, chlorine, bromine, iodine, methyl, fluoromethyl, chloromethyl, bromomethyl, iodomethyl, ethyl, fluoroethyl, chloroethyl, bromoethyl, iodoethyl, methoxy, fluoromethoxy, chloromethoxy, bromomethoxy, iodomethoxy, ethoxy, fluoroethoxy, chloroethoxy, bromoethoxy, or iodoethoxy.
In some typical embodiments, R6Selected from fluoro, methyl, one or more fluoro substituted methyl, methoxy or one or more fluoro substituted methoxy.
In some more typical embodiments, R6Selected from fluorine, -CF3or-OCF3。
In some embodiments, Cy is2Selected from phenyl, thienyl, furyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, pyridyl, pyrazinyl or pyrimidinyl; said groups being optionally substituted by one or more hydroxy, amino, nitro, cyano,Substitution; wherein R is8Is selected from C1-3An alkyl group.
In some typical embodiments, Cy2Selected from phenyl or pyridyl; said phenyl or pyridyl being optionally substituted by oneSubstitution; wherein R is8Selected from methyl or ethyl.
In some more typical embodiments, Cy2Is selected fromSaid group being optionally substituted by oneAnd (4) substitution.
In some embodiments, the aforementioned compound of formula (I) has the structure shown in formula (II),
wherein,
x is CH or N;
R3、R5、R7、Cy1as defined above for the compounds of formula (I).
In some embodiments, the compound of formula (I) of the present application is selected from the following compounds, or pharmaceutically acceptable salts thereof:
in another aspect, the present application relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as described herein. In some embodiments, the pharmaceutical compositions of the present application further comprise a pharmaceutically acceptable excipient.
The pharmaceutical compositions of the present application can be prepared by combining the compounds of the present application with suitable pharmaceutically acceptable excipients, for example, can be formulated into solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres, aerosols, and the like.
Typical routes of administration of a compound of the present application or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, intravenous administration.
The pharmaceutical compositions of the present application can be manufactured by methods well known in the art, such as conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, lyophilizing, and the like.
In some embodiments, the pharmaceutical composition is in an oral form. For oral administration, the pharmaceutical compositions may be formulated by mixing the active compounds with pharmaceutically acceptable excipients well known in the art. These adjuvants enable the compounds of the present application to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions and the like, for oral administration to a patient.
Solid oral compositions may be prepared by conventional mixing, filling or tableting methods. For example, it can be obtained by the following method: the active compounds are mixed with solid adjuvants, optionally the mixture obtained is milled, if desired with further suitable adjuvants, and the mixture is then processed to granules, to give tablets or dragee cores. Suitable excipients include, but are not limited to: binders, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, and the like.
The pharmaceutical compositions may also be adapted for parenteral administration, as sterile solutions, suspensions or lyophilized products in suitable unit dosage forms.
In another aspect, the present application relates to a method of treating a disease mediated by the ROR γ receptor in a mammal, comprising administering to a mammal, preferably a human, in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
In some embodiments, the dosage administered daily in all methods of administration of the compounds of formula (I) described herein is from 0.01 to 300mg/kg body weight, preferably from 10 to 300mg/kg body weight, more preferably from 25 to 200mg/kg body weight, in single or divided doses.
In another aspect, the present application relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for the prevention or treatment of a ROR γ receptor mediated disease.
Definition of
The following terms used in the present application have the following meanings, unless otherwise specified. A particular term should not be considered as ambiguous or unclear without special definition, but rather construed according to ordinary meaning in the art. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.
The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent, so long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., ═ O), meaning that two hydrogen atoms are substituted, oxo does not occur on the aryl.
The terms "optionally" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, ethyl is "optionally" substituted with one or more fluoro or chloro, meaning that the ethyl group may be unsubstituted (CH)2CH3) Monosubstituted (e.g. CH)2CH2F、CHClCH3) Polysubstituted (e.g. CHFCH)2F、CHClCHF2、CH2CHF2Etc.) or are taken entirelyGeneration (CCl)2CF3、CF2CF3). It will be appreciated by those skilled in the art that any group containing one or more substituents will not incorporate any substitution or substitution pattern which is sterically impossible and/or cannot be synthesized.
Herein Cm-nIt is the moiety that has an integer number of carbon atoms in the given range. E.g. "C1-6By "is meant that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.
When any variable (e.g., R) occurs more than one time in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 2R, then there are separate options for each R.
The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.
The term "hydroxy" refers to an-OH group.
The term "cyano" refers to the group — CN.
The term "amino" refers to the group-NH2A group.
The term "nitro" means-NO2A group.
The term "hydroxyalkyl" refers to-CnH2nAnd (5) OH. For example, hydroxymethyl means-CH2OH, 2-hydroxyethyl means-CH2CH2OH。
The term "alkyl" refers to a group of formula CnH2n+1A hydrocarbon group of (1). The alkyl group may be linear or branched. For example, the term "C1-6Alkyl "means an alkyl group having 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, and the like). Similarly, the alkyl portion (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl and alkylthio groups have the same definitions as above.
The term "alkoxy" refers to-O-alkyl.
The term "alkylamino" refers to-NH-alkyl.
The term "dialkylamino" refers to-N (alkyl)2。
The term "cycloalkyl" refers to a carbon ring that is fully saturated and may exist as a single ring, a bridged ring, or a spiro ring. Unless otherwise indicated, the carbocycle is typically a 3 to 10 membered ring. Non-limiting examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo [2.2.1] heptyl), bicyclo [2.2.2] octyl, adamantyl, and the like.
The term "cycloalkenyl" refers to a non-aromatic carbocyclic ring that is not fully saturated and may exist as a monocyclic, bicyclic, or spiro ring. Unless otherwise indicated, the carbocycle is typically a 5 to 8 membered ring. Non-limiting examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, and the like.
The term "heterocycloaliphatic" refers to a non-aromatic ring that is fully saturated or partially unsaturated (but not fully unsaturated heteroaromatic) and may exist as a monocyclic, bicyclic, or spiro ring. Unless otherwise indicated, the aliphatic heterocyclic ring is generally a 3 to 6 membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen and/or nitrogen. Non-limiting examples of lipoheterocyclyl groups include, but are not limited to, oxiranyl, tetrahydrofuryl, dihydrofuranyl, pyrrolidinyl, N-methylpyrrolidinyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, and the like.
The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated pi-electron system. For example, the aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and 1,2,3, 4-tetrahydronaphthalene, and the like.
The term "heteroaryl" refers to a monocyclic or fused polycyclic ring system containing at least one ring atom selected from N, O, S, the remaining ring atoms being C, and having at least one aromatic ring. Preferred heteroaryls have a single 4-to 8-membered ring, especially a 5-to 8-membered ring, or multiple fused rings containing 6 to 14, especially 6 to 10 ring atoms. Non-limiting examples of heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, and the like.
The term "treating" means administering a compound or formulation described herein to prevent, ameliorate or eliminate a disease or one or more symptoms associated with the disease, and includes:
(i) preventing the occurrence of a disease or condition in a mammal, particularly when such mammal is susceptible to the disease condition, but has not yet been diagnosed as having the disease condition;
(ii) inhibiting the disease or disease state, i.e., arresting its development;
(iii) alleviating the disease or condition, i.e., causing regression of the disease or condition.
The term "therapeutically effective amount" means an amount of a compound of the present application that (i) treats or prevents a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of a compound of the present application that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art with their own knowledge and this disclosure.
The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salts" includes, but is not limited to, acid addition salts of compounds of formula (i) with inorganic acids, acid addition salts of compounds of formula (i) with organic acids, or addition salts of compounds of formula (i) with acidic amino acids, and the like. The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application or salts thereof and pharmaceutically acceptable excipients. The purpose of the pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.
The term "pharmaceutically acceptable adjuvants" refers to those adjuvants which do not have a significant irritating effect on the organism and do not impair the biological activity and properties of the active compound. Suitable adjuvants are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and/or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
The words "comprise" or "comprise" and variations thereof such as "comprises" or "comprising," are to be understood in an open, non-exclusive sense, i.e., "including but not limited to.
Unless otherwise indicated, the abbreviations used in the present application have the following meanings
EDCI: 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride;
HOBt: 1-hydroxybenzotriazole;
TEA: triethylamine;
TLC: thin layer chromatography;
PE: petroleum ether;
EtOAc: ethyl acetate;
MeOH: methanol;
1M:1mol/L;
CDI: n, N' -carbonyldiimidazole;
DABCO: 1, 4-diazabicyclo [2.2.2] octane;
NH4OAc: acetic acid amine;
DMF: n, N-dimethylformamide;
n-BuOH: n-butanol;
KOH: potassium hydroxide;
HATU: 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethyluronium hexafluorophosphate;
DIPEA: n, N-diisopropylethylamine;
MsCl: methanesulfonyl chloride;
Pd(OAc)2: lead acetate;
DMSO, DMSO: dimethyl sulfoxide;
THF: tetrahydrofuran;
Pre-HPLC: preparing a liquid phase with high efficiency;
SFC: supercritical fluid chromatography;
LC-MS: liquid chromatography-mass spectrometry.
The intermediates and compounds of the present application may also exist in different tautomeric forms, and all such forms are included within the scope of the present application. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also referred to as proton transfer tautomers) include interconversion via proton migration, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is an imidazole moiety, wherein the proton can migrate between two ring nitrogens. Valence tautomers include interconversion by recombination of some of the bonding electrons. Exemplary enol tautomers are shown below, but are not limited thereto.
The present application also includes isotopically-labeled compounds of the present application, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as respectively2H、3H、11C、13C、14C、13N、15N、15O、17O、18O、31P、32P、35S、18F、123I、125I and36cl, and the like.
Certain isotopically-labelled compounds of the present application (e.g. with3H and14c-labeled ones) can be used in compound and/or substrate tissue distribution assays. Tritiated (i.e. by tritiation)3H) And carbon-14 (i.e.14C) Isotopes are particularly preferred for their ease of preparation and detectability. Positron emitting isotopes, such as15O、13N、11C and18f can be used in Positron Emission Tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present application can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
In addition, heavier isotopes are used (such as deuterium (i.e., deuterium)2H) Substitution may provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements), and thus may be preferred in certain circumstances where deuterium substitution may be partial or complete, partial deuterium substitution meaning that at least one hydrogen is substituted with at least one deuterium. Exemplary deuterated compounds are shown below, but are not limited thereto.
The compounds of the present application may be asymmetric, e.g., having one or more stereoisomers. Unless otherwise indicated, all stereoisomers include, for example, enantiomers and diastereomers. The compounds of the present application containing asymmetric carbon atoms can be isolated in optically active pure form or in racemic form. The optically active pure form can be resolved from a racemic mixture or synthesized by using chiral starting materials or chiral reagents. Non-limiting examples of stereoisomers include, but are not limited to:
the compounds of the present application may be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combinations thereof with other chemical synthetic methods, and equivalents thereof known to those skilled in the art, with preferred embodiments including, but not limited to, the examples of the present application.
The chemical reactions of the embodiments herein are carried out in a suitable solvent that is compatible with the chemical changes of the present application and the reagents and materials required therefor. In order to obtain the compounds of the present application, it is sometimes necessary for a person skilled in the art to modify or select the synthesis steps or reaction schemes based on the existing embodiments.
An important consideration in the art of synthetic route planning is the selection of suitable protecting Groups for reactive functional Groups (such as amino Groups in the present application), for example, reference may be made to Greene's Protective Groups in Organic Synthesis (4th Ed.) Hoboken, New Jersey: John Wiley & Sons, Inc. all references cited herein are incorporated herein in their entirety.
In some embodiments of the present application, the compounds of formula (II) are prepared by the synthetic routes shown below:
Detailed Description
The present invention is described in detail below by way of examples, but is not meant to be limited to any of the disadvantages of the present invention. Having described the invention in detail and having disclosed specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
Example 1
Step a: synthesis of Compound 1-2
To a solution of compound 1-1(25g) and N-methoxymethylamine hydrochloride (14.9g) in 500mL of dichloromethane were added TEA (51.6g,71.0mL), EDCI (36.7g) and HOBt (25.8 g). The reaction solution is reacted for 16 hours at the temperature of 10-20 ℃. TLC (PE: EtOAc ═ 1:1) showed the reaction was complete. The reaction mixture was dispersed in 500mL of methylene chloride and 500mL of water. The organic phase was washed once with 500mL of saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give the crude product. The crude product was passed through a flash column (220 g)Silica gel flash column, eluent: ethyl acetate, petroleum ether, gradient elution of eluent: 0-100% of petroleum ether/ethyl acetate (V/V); flow rate: 100mL/min) to obtain the compound 1-2.
1H NMR(400MHz,CHLOROFORM-d)δ3.71(s,3H),3.19(s,3H),2.62-2.74(m,1H),1.99-2.07(m,3H),1.92(br d,J=13.6Hz,2H),1.48-1.61(m,2H),1.32-1.44(m,2H);
19F NMR(400MHz,CHLOROFORM-d)δ=-73.8。
Synthesis of Compounds 1-3
A solution of compound 1-2(8.0g) in 100mL of tetrahydrofuran was added dropwise to a 50mL tetrahydrofuran suspension of lithium aluminum hydride (1.5g) at-65 ℃. After the dropwise addition is finished, the reaction solution reacts for 5 hours at the temperature of between 70 ℃ below zero and 65 ℃ below zero. TLC (PE: EtOAc ═ 5:1) showed complete reaction of compound 1-2. The reaction was quenched with MeOH (5.14g) at-65 ℃. When the temperature is increased to-10 ℃, 1M citric acid aqueous solution is dripped, the pH value is adjusted to be about 4, and the temperature is controlled to be-10 to-5 ℃ in the process. The resulting mixture was extracted with ethyl acetate (300mL x 3). The organic phases were combined, washed with 300mL of saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give the crude compound 1-3, which was used in the next step without further purification.
1HNMR(400MHz,CHLOROFORM-d)δ9.65(s,1H),2.09-2.16(m,1H),2.03-2.05(m,4H),1.92-1.99(m 1H),1.23-1.32(m,4H)。
Synthesis of Compounds 1-5
Compound 1-4(50.0g) was dissolved in N-methylpyrrolidone (500mL), and potassium carbonate (49.1g) and sodium ethylmercaptide (31.0g) were added to the reaction solution, and the mixture was stirred at 20 ℃ for 12 hours. When TLC (PE: EtOAc ═ 5:1) showed complete reaction of starting material, the reaction was poured into 1500mL of water and a solid precipitated, filtered and the filter cake was dried in vacuo to give compound 1-5.
MS:m/z 165.1[M+H]+。
Synthesis of Compounds 1-6
Compound 1-5(58.0g) was dissolved in methanol (600mL), a suspension of oxone complex salt (434.2g) in 900mL of water was added dropwise to the reaction solution at 0 ℃ and the reaction solution was stirred at 0-20 ℃ for 16 hours. When TLC (PE/EtOAc ═ 3:1) showed complete reaction of starting material. The reaction was filtered and excess oxone complex salt in the reaction was quenched with sodium thiosulfate. After removing methanol under reduced pressure, extracting with ethyl acetate (500 mL. times.2), combining the organic phases, washing with saturated brine (300mL), drying over anhydrous sodium sulfate, filtering, and concentrating the filtrate under reduced pressure to obtain crude compounds 1-6. And purifying the crude product by column chromatography (silica gel of 100-200 meshes, eluent comprising petroleum ether and ethyl acetate, and elution gradient comprising petroleum ether and ethyl acetate in a ratio of 10: 1-2: 1) to obtain a compound 1-6.
MS:m/z 197.0[M+H]+;
1H NMR(400MHz,CDCl3-d)δ9.13(d,J=1.6Hz,1H),8.38(dd,J=8.4,2.4Hz,1H),7.94(d,J=8.4Hz,1H),3.21(Q,J=7.2Hz,2H),1.35(d,J=7.6Hz,3H)。
Synthesis of Compounds 1-7
Compounds 1-6(10g) were dissolved in dry methanol (100.00mL), and dry palladium on carbon (10%, 0.58g) was added under nitrogen, and the mixture was replaced with nitrogen 3 times and then with hydrogen 3 times. Reaction solution in H2(50Psi) was stirred at 25 ℃ for 3 hours. When the LC-MS showed the reaction was complete, the reaction solution was filtered through Celite, and the filtrate was concentrated under reduced pressure to give compounds 1-17. MS M/z 201.0[ M + H ]]+;
1H NMR(400MHz,CDCl3)δ9.04(d,J=2.0Hz,1H),8.15(dd,J=2.4,8.4Hz,1H),7.56(d,J=8.4Hz,1H),4.12(s,2H),3.16(q,J=7.6Hz,2H),1.32(t,J=7.6Hz,3H).
Synthesis of Compounds 1-9
Compound 1-8(400.0g) was dissolved in anhydrous THF (1.5L), CDI (400.0g) was added at 15 ℃ and the reaction mixture was reacted at 15 ℃ for 1 hour. Anhydrous magnesium chloride (180.0g) and potassium salt of monoethyl malonate (400.0g) were then added. The mixture was stirred at 50 ℃ for 15 hours and LC-MS indicated that compounds 1-8 were completely reacted. To the reaction solution, 1.5L of water was added, extracted with ethyl acetate (1000 mL. times.2), and the organic phases were combined and washed once with 1L of saturated saline. Adding anhydrous sodium sulfate, drying, filtering, and concentrating the filtrate under reduced pressure to obtain residue. To the residue was added 1L of dichloromethane, stirred to give a suspension, filtered and the filter cake washed with dichloromethane (250 mL. times.3). The filtrates were combined and concentrated to give crude compounds 1-9, which were used directly in the next step without further purification.
MS:m/z 188.0[MDe-Boc+H]+;
1H NMR(400MHz,DMSO)δ5.11(m,1H),4.34(dd,J=8.8,4.0Hz,1H),4.23-4.19(m,2H),3.53(s,1H),2.5(m,1H),1.44(s,9H),1.27(m,4H),1.02(d,J=6.8,3H),0.83(m,3H)。
Synthesis of Compounds 1-10
Compound 1-9(600.0g) was dissolved in tetrahydrofuran (2500mL), potassium tert-butoxide (225.0g) was added at 0 ℃ and the reaction mixture was reacted at 15 ℃ for 60 minutes. DABCO (210.0g) and Compound A (870.0g) were then added sequentially. The reaction solution was stirred at 15 ℃ for 1 hour, and NH was added to the reaction solution4OAc ((300.0 g.) the reaction was then stirred at 15 ℃ for 13 hours LC-MS showed the starting material reacted completely, 4.0L of water was added to the reaction, extracted with ethyl acetate (1000mL x 3), the organic phases combined, washed once with 1L of saturated saline, dried over anhydrous sodium sulfate added, filtered, the filtrate concentrated under reduced pressure to give a residue, which was purified by column chromatography (silica, eluent gradient elution: petroleum ether: ethyl acetate: 100: 0-5: 1) to give compounds 1-10.
MS:m/z 357.1[M+H]+;
1H NMR(400MHz,CDCl3)δ8.61(d,J=5.6Hz,1H),8.19(d,J=5.6Hz,1H),5.73(d,J=9.6Hz,1H),5.61(dd,J=9.6,5.2Hz,1H),4.47-4.38(m,2H),2.08-2.00(dt,J=17.2,6.8Hz,1H),1.40-1.44(m,12Hz),0.94(d,J=6.8Hz,3H),0.84(d,J=9.2Hz,3H)。
Synthesis of Compounds 1-11
Compounds 1-10(60.0g) were dissolved in absolute ethanol (500.0mL) and NaBH was added portionwise at 0 deg.C4(12.7g) and CaCl2(18.7g), and maintaining the temperature of the reaction solution at 0-5 ℃. After the completion of the dropwise addition, the reaction solution was stirred at 0 ℃ for 90 minutes. LC-MS showed the starting material reaction was complete. The reaction was quenched by the addition of 1000mL of saturated ammonium chloride solution at 0 ℃. Then, ethyl acetate was added for extraction (500 mL. times.3), the organic phases were combined and washed with 1L of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compounds 1-11.
MS:m/z 315.0[M+H]+;
1H NMR (400MHz, CDCl3) δ 8.47(d, J ═ 2.4Hz,1H),7.68(d, J ═ 2.4Hz,1H),5.39-5.46(m,1H),5.00(d, J ═ 12.0Hz,1H),4.55(t, J ═ 9.2Hz,1H),4.35-4.47(m,2H),2.10-2.20(m,1H),1.37(s,9H),1.10(d, J ═ 6.8Hz,3H),0.70(d, J ═ 6.8Hz, 3H). Synthesis of Compounds 1-12, 1-13
Compounds 1-11(53g) and TEA (25.6g,35.0mL) were dissolved in 500mL of dichloromethane. To this solution was added MsCl (24.9g,16.8mL) dropwise at 0 ℃. After the dropwise addition, the reaction solution is stirred for 16 hours at 15-25 ℃. LC-MS showed the starting material reaction was complete. The reaction was quenched by the addition of 500mL of saturated sodium bicarbonate solution and extracted with ethyl acetate (500 mL. times.2). The organic phases were combined, washed with 500mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude product of a mixture of compounds 1-12 and compounds 1-13 (molar ratio about 1: 1). The crude product was used directly in the next step without further purification.
Compounds 1-12, MS: M/z 276.9[ Mde-56+H]+;
Compounds 1-13, MS M/z 337.0[ M ]de-56+H]+。
Synthesis of Compounds 1-14
A mixture of compounds 1-12 and compounds 1-13 (62g, molar ratio about 1:1) was dissolved in 500mL of anhydrous THF. NaH (24.4g, 60% pure) was added to the solution in portions at 0 ℃ and the temperature was maintained at 0-5 ℃. After the addition is finished, the reaction solution is stirred for 16 hours at 15-25 ℃. LC-MS showed the maintenance of the starting material and NaI (15g) was added to the mixture. And after the addition is finished, continuously stirring the reaction solution for 16 hours at the temperature of 15-25 ℃. LC-MS shows disappearance of the raw material and generation of the product. The reaction mixture was quenched with 500mL of saturated ammonium chloride solution at 25 ℃ and extracted with aqueous ethyl acetate (500 mL. times.2). The combined organic phases were washed with 500mL of saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give the crude product. The crude product was passed through a flash column (120 g)Silica gel flash column, gradient elution of eluent: 0-28% of ethyl acetate/petroleum ether (V/V); flow rate: 85mL/min, and purifying to obtain the compounds 1-14.
MS:m/z 297.1[M+H]+;
1H NMR(400MHz,CHLOROFORM-d)δ8.43(s,1H),7.48-7.59(m,1H),4.69-4.98(m,2H),4.45-4.55(m,1H),2.33-2.59(m,1H),1.51(s,9H),0.98-1.10(m,3H),0.69-0.81(m,3H)。
Synthesis of Compounds 1-15
To a solution of compounds 1-14(50.0g) in 250mL anhydrous DMF and 250mL n-BuOH (250mL) at 25 deg.C was added Pd (OAc)2(1.89g), Compound B (10.3g) and K2CO3(34.9 g). The reaction solution was evacuated and carbon monoxide gas-displaced 3 times. Then stirring for 16 hours at 100 ℃ under the atmosphere of carbon monoxide gas. LC-MS showed disappearance of starting material. The solvent was removed under vacuum, and 250mL of aqueous KOH (1M) and 250mL of ethanol were added to the residue and stirred for 2 hours. LC-MS showed the formation of compounds 1-15. The mixed solution was concentrated to a volume of 250 mL. The pH value is adjusted to 3-5 by 1M hydrochloric acid, and ethyl acetate (500mL x 2) is added for extraction. The combined organic phases were dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give the crude product. The crude product was used directly in the next step without further purification.
MS:m/z 307.1[M+H]+;
1H NMR(400MHz,CHLOROFORM-d)δ9.21(s,1H),9.05(s,1H),8.19-8.29(m,1H),4.76-5.13(m,2H),4.57(d,J=15.6Hz,1H),2.38-2.63(m,1H),1.53(s,9H),0.96-1.09(m,3H),0.74-0.85(m,3H)。
Synthesis of Compounds 1-16
Compounds 1-15(8.0g, ca.) were dissolved in anhydrous DMF (100mL), to which HATU (14.9g, ca.), compounds 1-7(5.8g) and DIPEA (10.1g,13.6mL) were added in that order, and the reaction was stirred at 20 ℃ for 2 hours. When the LC-MS showed the reaction was complete, the reaction was concentrated under reduced pressure to remove DMF, diluted with 120mL of water and extracted with dichloromethane (200mL x 3). The combined organic phases were washed with 150mL of saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure to give the crude product. The crude product is subjected to flash column chromatography (40 g)Silica gel flash column, gradient elution of eluent: 0-100% of petroleum ether/ethyl acetate (V/V); flow rate: 35mL/min) to yield compounds 1-16.
MS:m/z 489.2[M+H]+;
1H NMR(400MHz,CDCl3)δ8.98(d,J=2.0Hz,1H),8.91(s,1H),8.12(dd,J=8.0,2.4Hz,1H),7.96-8.03(m,1H),7.55(br s,1H),7.50(d,J=8.0Hz,1H),4.88(br d,J=11.2Hz,1H),4.85-4.85(m,1H),4.83(d,J=5.2Hz,1H),4.50(br t,J=14.4Hz,1H),3.10(q,J=7.2Hz,2H),2.66-2.94(m,1H),2.23-2.59(m,1H),1.45(s,9H),1.26(t,J=7.2Hz,3H),0.89-1.05(m,3H),0.62-0.76(m,3H)。
Synthesis of Compounds 1-17
Xylene (50.00mL) was preheated to 80 ℃ and then compounds 1-16(3.1g) were slowly added to xylene to dissolve them sufficiently, and Lawson's reagent (1.00g) was added to the reaction solution at 80 ℃. The reaction mixture was stirred at 80 ℃ for 1 hour under nitrogen. When LC-MS showed the reaction was complete, the reaction was concentrated under reduced pressure to remove xylene, diluted with 80mL of water and extracted with dichloromethane (200mL x 2), the combined organic phases were washed with 100mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product which was purified by column chromatography (80 g of column chromatography)Silica gel flash column, eluent: petroleum ether, ethyl acetate; elution gradient is 0-80%; flow rate: 35mL/min) to yield compounds 1-17.
MS:m/z 505.1[M+H]+;
1H NMR(400MHz,CDCl3)δ9.49(br s,1H),8.99(br s,2H),8.16(br d,J=8.0Hz,2H),7.56(brd,J=7.6Hz,1H),5.16(br s,2H),4.39-4.59(m,1H),3.66-3.85(m,2H),3.10(q,J=7.6Hz,2H),2.25-2.58(m,1H),1.45(s,9H),1.25(t,J=7.6Hz,3H),0.84-1.07(m,3H),0.63-0.84(m,3H)。
Synthesis of Compounds 1-18
Compounds 1-17(3.1g) were dissolved in hydrochloric acid-dioxane (30.00mL) and stirred at 20 ℃ for 1 hour. When the reaction was complete as shown by LC-MS, the reaction was concentrated under reduced pressure to remove dioxane, and the residue was dissolved in dichloromethane (30.00mL) and water (20.00mL), adjusted to pH 8 by the addition of saturated sodium bicarbonate solution, and then extracted with dichloromethane (25mL x 2). The combined organic phases were washed with 30.00mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give crude compounds 1-18. The crude product was used directly in the next step without further purification.
MS:m/z 405.1[M+H]+。
Synthesis of the Compound of example 1
Compounds 1-18(2.5g) and compounds 1-3(2.2g) were dissolved in methanol (30mL) and acetic acid (371.1mg) was added to adjust the pH to 5, then sodium cyanoborohydride (1.6g) was added slowly and the reaction stirred at 70 ℃ for 1 hour. When the LC-MS showed the reaction was complete, the reaction was quenched with saturated sodium bicarbonate solution, concentrated under reduced pressure to remove methanol, diluted with water (15mL), and extracted with dichloromethane (30mL × 3). The combined organic phases were washed with brine (20mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give crude Compound 1. The crude product was separated by pre-HPLC (formic acid system) and SFC (column: Chiralpak AD-350 x 4.6mm I.D.,3um mobile phase: A: CO2, B: isopropanol (0.05% DEA); gradient: maintaining B fraction 5% for 0.2 min, then 1.4 min the B fraction content was ramped from 5% to 40% and maintaining B fraction content 40% for 1.05 min, then the B fraction was ramped to 5% for 0.35 min; flow rate: 4mL/min column temperature: 40 ℃ C.) to give the compound of example 1 in free form.
The free compound was dissolved in acetonitrile and water, and 2.29mL of 1M hydrochloric acid was added to the solution at 0 ℃ and lyophilized to give the compound of example 1.
MS:m/z 569.1[M+H]+;
1H NMR(400MHz,CDCl3)δ9.20-9.45(m,1H),9.08(s,1H),8.90(br s,1H),8.20-8.31(m,1H),8.10(br s,1H),7.60(d,J=8.28Hz,1H),5.22(d,J=4.27Hz,2H),4.89(br s,1H),4.38(br s,1H),3.20(q,J=7.36Hz,2H),2.62(br s,1H),2.13-2.34(m,1H),2.02(br d,J=8.53Hz,3H),1.24-1.45(m,8H),1.22(br d,J=6.02Hz,1H),0.70-1.17(m,8H)。
Example 2
The compound of example 2 was prepared by substituting 3-fluoro-4-trifluoromethoxybenzaldehyde for the compounds of formulae 1-3, according to the preparation of the compound of example 1 in free form.
MS:m/z 597.1[M+H]+;
1HNMR(400MHz,METHANOL-d4)δ8.82-8.96(m,1H),8.76(s,1H),8.15(dd,J=8.4,2.4Hz,1H),7.94(s,1H),7.56(d,J=8.4Hz,1H),7.21-7.36(m,3H),5.09-5.16(m,2H),4.05-4.20(m,2H),3.94-4.04(m,1H),3.72(d,J=14.8Hz,1H),3.56-3.67(m,1H),3.15-3.19(m,2H),2.20(td,J=7.2,2.8Hz,1H),1.15(br t,J=7.6Hz,3H),0.95(br d,J=7.2Hz,3H),0.87-0.93(m,3H)。
Example 3
Example 3 was prepared by substituting 2, 2-difluoro-5-formylbenzodioxole for the compound of formula 1-3, according to the method for preparation of the compound of example 1 in free form.
MS:m/z 575.1[M+H]+;
1H NMR(400MHz,METHANOL-d4)δ8.89(br s,1H),8.76(s,1H),8.13-8.20(m,1H),7.94(s,1H),7.56(br d,J=8.0Hz,1H),7.22(s,1H),7.14(br d,J=8.0Hz,1H),7.05-7.10(m,1H),5.11(s,2H),4.07-4.17(m,2H),3.99(br s,1H),3.61-3.74(m,2H),3.15-3.19(m,2H),2.15-2.26(m,1H),1.15(br t,J=7.2Hz,3H),0.93(br dd,J=12.8,6.80Hz,6H)。
Example 4
The compound of example 4 was prepared by following the procedure for the preparation of example 1 in free form, replacing the compound of formula 1-3 with 3, 5-difluoro-4-trifluoromethoxybenzaldehyde.
MS:m/z 615.1[M+H]+;
1H NMR(400MHz,CHLOROFORM-d)δ9.28(br s,1H),9.07(d,J=2.0Hz,1H),8.89(s,1H),8.24(dd,J=8.4,2.4Hz,1H),8.04(s,1H),7.59(d,J=8.4Hz,1H),7.46-7.53(m,1H),7.05(td,J=8.8,1.6Hz,1H),5.21(d,J=4.4Hz,2H),4.26(br d,J=13.6Hz,1H),4.04-4.14(m,2H),3.93(d,J=14.4Hz,1H),3.73(br d,J=14.4Hz,1H),3.19(q,J=7.2Hz,2H),2.32(qd,J=6.8,4.0Hz,1H),1.34(t,J=7.2Hz,3H),1.08(d,J=6.8Hz,3H),1.02(d,J=6.8Hz,3H)。
Biological activity experiment 1: in vitro ROR γ inhibitory Activity assay
The test method comprises the following steps:
a reporter cell: reporter cells expressing chimeric ROR gamma receptors were used in this experiment. The N-terminal DNA binding domain of the chimeric ROR γ receptor, i.e. the native ROR γ protein, was replaced with the DNA binding domain of the yeast Gal4 protein. The reporter luciferase is located downstream of the Gal4 activation sequence (UAS). As shown in the following table:
step 1: reporter cells were prepared as cell suspensions using INDIGO cell recovery medium (CRM, containing 5% charcoal treated fetal bovine serum). The cell suspension was dispensed into a white 96-well plate at 100. mu.l/well.
Step 2: 8 concentration gradients were set for each test compound, and each concentration was tested 2 times. Prior to the experiment, master stocks of test compounds were serially diluted in DMSO to prepare "1000X-concentration" solutions for each final test concentration. Subsequently, the compounds were further diluted with cell recovery medium (CRM, containing 5% charcoal treated fetal bovine serum) to prepare a "2X-concentration" of test working solution. Test solutions were added to test wells pre-loaded with reporter cells at a volume of 100 μ l/well to obtain the desired final test concentration. The residual concentration of DMSO in all test wells was 0.1%. The test plate was incubated for 24 hours in a cell incubator, which set the conditions: the temperature is 37 ℃, the CO2 is 5 percent, and the humidity is 85 percent.
And step 3: after 24 hours of incubation, the plate was discarded, 100 microliters of luciferase assay was added to each test well, and the fluorescence intensity in each well was read (Relative Luminescence Units, RLUs).
And (3) testing:
the test uses the reference compound ursolic acid as an internal standard of a positive compound to confirm the inhibition effect of the test compound on ROR gamma in a specific batch of report cells. The test of the reference compound and the test compound is performed simultaneously and is therefore exposed to the same test reagents and environment. The reference compound group containing 0.1% DMSO as solvent was used as an internal positive compound standard to determine the effect of DMSO as solvent on the test results and to calculate the percent ROR γ activity reduction.
Data processing:
the test data was managed and archived by microsoft Excel and the mean +/-Standard Deviation (SD), fold reduction, inhibition, coefficient of variation (% CV) and Z factor of RLU were calculated, where:
coefficient of variation (% CV): 100 [ (SD/ave. rlu) ];
fold reduction in inverse agonists: RLU [ AveSolvent/Ave.RLUTest compounds];
Percent reduction in inverse agonist: 100 (1- [ AveTest compounds/Ave.RLUSolvent]);
The theoretical minimum reduction (0% reduction) is for the solvent control without compound;
factor Z: 1- [ (3. multidot. SD)Solvent+SDTest compounds])/(RLUSolvent_RLUTest compounds)]。
The graphic data processing method comprises the following steps:
dose Response Curves (DRC) for ROR γ tests for reference and test compounds were obtained by nonlinear fitting of the log values of ROR γ activity inhibition and compound concentration by GraphPad Prism software.
And (3) testing results:
results of in vitro screening assays for the compounds of the examples are detailed in Table 1
TABLE 1 in vitro screening test results for the compounds of the invention
Definition of biological activity: a: EC (EC)50≤100nM;B:100nM<EC50≤500nM;C:500nM<EC50≤1000nM;D:1000nM<EC50≤5000nM;
And (4) experimental conclusion: in the in vitro ROR γ activity test, the compounds of the examples all showed strong inhibitory activity against ROR γ.
Biological activity experiment 2: pharmacokinetic evaluation
Balb/c mice (female, 15-30g, 7-9 weeks old, Shanghai Ling Chang) were used to test the in vivo pharmacokinetics of the compounds, with the experimental method as follows:
rodent pharmacokinetic characteristics after intravenous injection and oral administration of the compound are tested by a standard scheme, and the candidate compound is prepared into a clear solution in an experiment and is administered to mice by single intravenous injection and single oral administration. The Intravenous (IV) vehicle was a mixture of 5% DMSO and 95% 10% Cremophor EL, and the oral (PO) vehicle was a mixture of 1% tween80, 9% PEG400, and 90% water. Collecting a whole blood sample within 48 hours, centrifuging for 15 minutes at 3000g at 4 ℃, separating supernatant to obtain a plasma sample, adding 20 times of acetonitrile solution containing an internal standard for precipitating protein, centrifuging to obtain supernatant, adding equal times of water into the supernatant, centrifuging again, taking supernatant for sampling, quantitatively analyzing blood concentration by an LC-MS/MS analysis method, and calculating drug substitution parameters such as peak reaching concentration, peak reaching time, clearance rate, half-life period, area under a drug time curve, bioavailability and the like. The test results are shown in Table 2.
The term "10% Cremophor EL" refers to a 10% Cremophor EL deionized water solution, for example, taking 10ml Cremophor EL as an example of 100ml preparation, adding deionized water, stirring uniformly, and adding deionized water to make the total volume 100 ml. "a mixed solvent of 5% DMSO and 95% 10% Cremophor EL" refers to a mixed solvent of DMSO and 10% Cremophor EL, wherein DMSO 10% Cremophor EL and 10% Cremophor EL account for 95% of the volume of the mixed solvent.
"internal standards" include, but are not limited to, 100ng/mL Labetalol, 100ng/mL dexamethasone, 100ng/mL Tolbutamide, 100ng/mL Verapamide, 100ng/mL Glyburide, or 100ng/mL Celecoxib in ACN.
Table 2 PK parameters in plasma of compounds of examples
Biological activity experiment 3: hERG potassium channel inhibition assay
1. Purpose of the experiment:
the influence of the embodiment 1 to be tested on the hERG potassium channel is detected by a full-automatic patch clamp method.
2. Experimental methods
2.1. Cell culture
The experiment used stable expression of hERG potassium channel cells from Aviva Biosciences CHO-hERE, CHO-hERG cultured in 5% CO2And at 37 ℃. The CHO hERG culture broth is shown in Table 3.
TABLE 3 CHO hERG culture broth
Reagent | Supplier | Catalog Number | Volume(mL) |
F12 Hams | Invitrogen | 31765-092 | 500 |
FBS | Invitrogen | 10099-141 | 50 |
G418/Geneticin | Invitrogen | 10131-027 | 1 |
Hygromycin B | Invitrogen | 10687-010 | 1 |
2.2. Pre-preparation of cells
The CHO-hERG cells prepared for the experiment were cultured for at least two days or more and the cell density reached 75% or more. Before the experiment began, cells were digested with TrypLE and then resuspended with extracellular fluid to collect cells.
2.3. Preparation of intracellular and extracellular fluids
The extracellular fluid needs to be prepared once a month. The intracellular fluid should be frozen at-20 deg.C. The intracellular and extracellular fluid compositions are shown in Table 4.
TABLE 4 intracellular and extracellular fluid composition
Composition of matter | Extracellular fluid (mM) | Intracellular fluid (mM) |
NaCl | 145 | ‐ |
KCl | 4 | 120 |
KOH | ‐ | 31.25 |
CaCl2 | 2 | 5.374 |
MgCl2 | 1 | 1.75 |
Glucose | 10 | ‐ |
Na2ATP | ‐ | 4 |
HEPES | 10 | 10 |
EGTA | ‐ | 10 |
pH | 7.4 with NaOH | 7.2 with KOH |
Osmotic pressure | 295mOsm | 285mOsm |
2.4. Preparation of the Compounds
Dissolving a compound to be detected and positive control Amitriptyline into stock solution with a certain concentration by DMSO, then diluting according to different gradients, and finally adding the stock solution into extracellular fluid according to a certain proportion to dilute the stock solution into the concentration to be detected. The presence or absence of the precipitate was checked visually before the start of the experiment. Finally, the concentration of DMSO in the solution to be tested and the positive control Amitriptyline cannot exceed 0.3 percent at most.
2.5. Voltage stimulation protocol
Keeping the clamping potential at-80 mv, firstly giving a voltage stimulus of-50 mv, lasting for 80ms to record the cell leakage current value, then depolarizing to +20mv, maintaining for 4800ms, opening the channel of hERG, then repolarizing to-50 mv and maintaining for 5000ms, leading out the tail current of hERG and recording, and finally, restoring the voltage to the clamping potential of-80 mv, and maintaining for 3100 ms. The above voltage stimulation was repeated every 15000 ms.
2.6.QPatchHTXWhole cell patch clamp recordings
hERG QPatchHTXThe experiments were performed at room temperature. Whole cell protocols, voltage stimulation protocols and compound detection protocols were established on QPatch Assay Software 5.2 (pH Bioscience) Software.
The voltage stimulation was first repeated 30 times, this segment being the baseline region for subsequent analysis, followed by the addition of 5 μ l of extracellular fluid, repeated three times. The effect concentration of each compound was added sequentially, again in a volume of 5 μ l three times. Cells were incubated at least 5mins per concentration tested. In the whole recording process, each index needs to reach the data analysis receiving standard, if the index does not reach the standard, the cell is not counted in the analysis range, the compound is tested again, and the recording process is automatically operated by Qpatch analysis software. Each compound was tested at a concentration of 0.24. mu.M, 1.20. mu.M, 6.00. mu.M, 30.00. mu.M in sequence, at least two cells were repeated at each concentration.
2.7. Data analysis
In each complete current record, the percent inhibition of the effect concentration of each compound was calculated based on the percentage of peak current in the negative control. Fitting by using a standard equation of Hill form to obtain a dose-effect relationship curve, wherein the specific equation is as follows:
I(C)=Ib+(Ifr-Ib)*cn/(IC50 n+cn)
c is the test concentration of the compound and n is the slope
The curve fitting and the inhibition rate calculation are both completed by the analysis of Qpatch analysis software, and if the inhibition rate at the lowest concentration exceeds half inhibition or the inhibition rate at the highest concentration does not reach half inhibition, the corresponding IC of the compound50Below minimum concentration or IC50The value is greater than the maximum concentration.
2.8. Test results
The results of the hERG IC50 values for the example compounds are shown in table 5.
TABLE 5 results for hERG IC50 values for the compounds of the examples
Claims (3)
2. a pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.
3. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 2, for the preparation of a medicament for preventing or treating a ROR γ receptor mediated disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710552918 | 2017-07-07 | ||
CN2017105529180 | 2017-07-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109206423A CN109206423A (en) | 2019-01-15 |
CN109206423B true CN109206423B (en) | 2021-06-25 |
Family
ID=64989879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810731382.3A Active CN109206423B (en) | 2017-07-07 | 2018-07-05 | Thioamide substituted dihydropyrrolopyridine compounds as ROR gamma inhibitors |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109206423B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105940002A (en) * | 2014-02-03 | 2016-09-14 | 生命医药公司 | Dihydropyrrolopyridine inhibitors of ROR-gamma |
CN106232582A (en) * | 2014-04-16 | 2016-12-14 | 格兰马克药品股份有限公司 | Aryl and heteroaryl ether compound as ROR gamma modulators |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9663515B2 (en) * | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
-
2018
- 2018-07-05 CN CN201810731382.3A patent/CN109206423B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105940002A (en) * | 2014-02-03 | 2016-09-14 | 生命医药公司 | Dihydropyrrolopyridine inhibitors of ROR-gamma |
CN106232582A (en) * | 2014-04-16 | 2016-12-14 | 格兰马克药品股份有限公司 | Aryl and heteroaryl ether compound as ROR gamma modulators |
Also Published As
Publication number | Publication date |
---|---|
CN109206423A (en) | 2019-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020111593A (en) | Naphthyridine compounds as JAK kinase inhibitors | |
CN109867676B (en) | Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof | |
CN114616232A (en) | Azepadinopyrimidine derivatives and medical application thereof | |
AU2018314980B2 (en) | Diarylthiohydantoin compound as androgen receptor antagonist | |
JP6337218B2 (en) | Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators | |
CN111961034A (en) | Compounds useful as RET kinase inhibitors and uses thereof | |
EP3929185A1 (en) | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof | |
CN113166061B (en) | ROR gamma inhibitors containing sulfonyl structures | |
JP2021119163A (en) | Memantine compounds and their preparation and uses thereof | |
AU2021389180A9 (en) | Heteroaryl carboxamide compound | |
CN110945002B (en) | Bicyclic compounds as ROR gamma inhibitors | |
CN116801883A (en) | Heteroaromatic ring compounds, preparation method and application thereof | |
AU2020410900B2 (en) | Compound used as RET kinase inhibitor and application thereof | |
BR112016001238B1 (en) | 1-(PIPERAZIN-1-IL)-2-([1,2,4]TRIAZOLE-1-IL)-ETHANONE DERIVATIVES, THEIR USES AND PHARMACEUTICAL COMPOSITION INCLUDING THEM | |
CN109206423B (en) | Thioamide substituted dihydropyrrolopyridine compounds as ROR gamma inhibitors | |
EP3686197B1 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
EP4403558A1 (en) | Azaindazole macrocyclic compound and use thereof | |
CN115433179A (en) | Benzopyrimidine compounds and medical application thereof | |
CN113896669A (en) | Estrogen receptor modulators and uses thereof | |
CN114014890A (en) | Compound with RIP2 kinase inhibitory activity, pharmaceutical composition containing same, and application thereof | |
CN115466257A (en) | Compound with TYK2 inhibitory activity, pharmaceutical composition containing same, and application thereof | |
EP4029858A1 (en) | Pyrimidine compound and preparation method therefor | |
CN114929702A (en) | Diarylthiohydantoin compounds as AR antagonists | |
CN109134476B (en) | Bridged ring piperazine derivative or salt thereof, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |